Merck & Co., Inc. $MRK Stock Position Increased by Dai ichi Life Insurance Company Ltd

Key Points

• Dai ichi Life Insurance Company Ltd increased its Merck stake by 18.2% in the first quarter, buying 41,648 shares to bring its total holdings to 270,465 shares valued at about $32.5 million.
• Merck’s HIV pipeline drew attention after it announced initial access plans for alimatravir, a once-monthly oral HIV PrEP in Phase 3 development, along with licensing agreements covering 129 countries.
• The company faces a competitive headwind as Par Health launched the first generic version of Janumet XR in the U.S., which could pressure Merck’s diabetes-related sales.

Dai ichi Life Insurance Company Ltd increased its position in Merck & Co., Inc. (NYSE:MRK - Free Report) by 18.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 270,465 shares of the company's stock after buying an additional 41,648 shares during the quarter. Merck & Co., Inc. comprises approximately 0.9% of Dai ichi Life Insurance Company Ltd's holdings, making the stock its 18th largest position. Dai ichi Life Insurance Company Ltd's holdings in Merck & Co., Inc. were worth $32,534,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Kingdom Financial Group LLC. acquired a new position in Merck & Co., Inc. in the fourth quarter worth approximately $25,000. Prosperity Bancshares Inc bought a new position in shares of Merck & Co., Inc. in the fourth quarter valued at $26,000. Abound Financial LLC acquired a new stake in shares of Merck & Co., Inc. during the 4th quarter valued at $26,000. IFC & Insurance Marketing Inc. acquired a new stake in shares of Merck & Co., Inc. during the 4th quarter valued at $31,000. Finally, High Note Wealth LLC boosted its stake in shares of Merck & Co., Inc. by 58.9% during the 4th quarter. High Note Wealth LLC now owns 294 shares of the company's stock worth $31,000 after acquiring an additional 109 shares in the last quarter. 76.07% of the stock is owned by institutional investors and hedge funds.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck announced initial access plans for alimatravir, its investigational once-monthly oral HIV PrEP in Phase 3 development, and said it has signed voluntary licensing agreements covering 129 countries. That broad access strategy could support adoption in large international markets if the drug is approved. Article Title
• Neutral Sentiment: Merck also issued a company release on the same alimatravir access plan, reinforcing that the program is moving forward and that it is trying to expand availability in regions that account for most new HIV diagnoses globally. Article Title
• Neutral Sentiment: Traders also bought a high volume of Merck call options, which may reflect rising bullish speculation around the stock and the HIV pipeline, but it does not by itself change fundamentals. Article Title
• Negative Sentiment: Par Health launched the first generic version of Janumet XR in the U.S., which may pressure Merck’s diabetes-related sales and adds another competitive headwind for an established product. Article Title

Merck & Co., Inc. Price Performance

MRK opened at $131.06 on Friday. The stock has a fifty day moving average of $121.67 and a 200-day moving average of $117.71. The firm has a market capitalization of $323.68 billion, a P/E ratio of 36.92, a PEG ratio of 5.18 and a beta of 0.19. Merck & Co., Inc. has a 12-month low of $76.66 and a 12-month high of $131.74. The company has a quick ratio of 1.06, a current ratio of 1.30 and a debt-to-equity ratio of 1.02.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last issued its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, beating analysts' consensus estimates of ($1.47) by $0.19. The business had revenue of $16.29 billion for the quarter, compared to the consensus estimate of $15.85 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.Merck & Co., Inc.'s revenue for the quarter was up 4.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.22 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Equities analysts forecast that Merck & Co., Inc. will post 2.74 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, July 8th. Shareholders of record on Monday, June 15th were paid a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a yield of 2.6%. The ex-dividend date of this dividend was Monday, June 15th. Merck & Co., Inc.'s payout ratio is 95.77%.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on MRK shares. Bank of America lifted their target price on Merck & Co., Inc. from $130.00 to $141.00 and gave the stock a "buy" rating in a report on Tuesday, June 30th. JPMorgan Chase & Co. upped their target price on Merck & Co., Inc. from $135.00 to $140.00 and gave the company an "overweight" rating in a report on Monday, July 13th. Guggenheim lifted their price target on Merck & Co., Inc. from $140.00 to $145.00 and gave the stock a "buy" rating in a research note on Monday, July 13th. UBS Group boosted their price objective on Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a "buy" rating in a report on Monday, April 13th. Finally, CICC Research assumed coverage on shares of Merck & Co., Inc. in a research note on Wednesday, June 24th. They set an "outperform" rating and a $138.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and seven have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $133.94.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.